Another study showed that the CXCR4 inhibitor, AMD3100, improved the antimetastatic potential of conventional anticancer drug (etoposide and cisplatin) combinations in an animal model of small cell lung cancer, SCLC [137]. Here, CXCR4 is linked to small cell lung carcinoma.